Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Voxzogo
Pharma
BioMarin's hemophilia gene therapy needs 3 stars to align: CEO
BioMarin's Roctavian only sold $3.5 million in 2023, as new CEO Alexander Hardy looks to the next two years to prove the gene therapy's value.
Angus Liu
Feb 23, 2024 10:15am
BioMarin’s commercial chief Jeffrey Ajer hits the exit
Jan 12, 2024 10:28am
JPM24: New BioMarin CEO Hardy makes his priorities clear
Jan 10, 2024 11:29am
Activist investor Elliott takes $1B stake in BioMarin: report
Nov 8, 2023 8:25am
BioMarin's barnstorming Voxzogo launch creates supply bottleneck
Aug 3, 2023 7:45am
After delays at the FDA, BioMarin's gene therapy snags EU nod
Aug 25, 2022 9:41am